BioSpace News Archive

The prevalence of arrhythmia and cardiovascular diseases is rising and expected to continue growing throughout the forecast period. According to the latest research by the company, the global temporary cardiac pacing wires & leads market is anticipated to account for over US$ 411.5 Mn in terms of value by 2026 end. The report on the temporary cardiac pacing wires & leads market indicates that the market is projected to have significant growth potential through 2022.

IntraOp Medical Corporation announced today the first patient enrolled in the Cosmopolitan Trial: A randomized study of single treatment electron-beam intraoperative radiation therapy (IORT) delivered during surgery compared to external beam radiation therapy which is delivered over 3-4 weeks.

CPhI & P-MEC China 2020, the landmark 20th anniversary edition of China’s largest pharma exhibition, will now take place on 16-18 December 2020 at SNIEC in Shanghai [rescheduled from June 22-24, 2020].

TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its 510(k) application for the potential clearance of its TearLab Discovery™ MMP-9 Test, the Company’s next-generation in-vitro diagnostic testing system.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2020 at 4:00 PM Eastern Time.

Rocket Pharmaceuticals, Inc. today announces the appointment of Elisabeth Bjӧrk, M.D., Ph.D. to its Board of Directors.

Emergex Signs Agreement with GEORGE MASON UNIVERSITY for Highly Pathogenic RNA Virus Studies

Founded in 2012, New York City headquartered, Paragon Private Health (Paragon) helps create, implement and manage customized concierge medicine programs with private practice physicians to provide enhanced care for patients

Dr. Richard Whitley, a Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and Neurosurgery Joins Moleculin’s Science Advisory Board

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces the following statement regarding the impact of the COVID-19 pandemic on the company’s ongoing clinical development efforts: First, we would like to express our sincerest gratitude for all of the healthcare workers and other res